The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region
|
|---|---|
| Published in |
Frontiers in Pharmacology, August 2017
|
| DOI | 10.3389/fphar.2017.00576 |
| Pubmed ID | |
| Authors |
Aníbal García-Sempere, Daniel Bejarano-Quisoboni, Julián Librero, Clara L. Rodríguez-Bernal, Salvador Peiró, Gabriel Sanfélix-Gimeno |
| Abstract |
Introduction: Beyond clinical trials, clinical practice guidelines, and administrative regulation, treatment decision-making can be influenced by individual and contextual factors. Our goal was to describe variations in the patterns of initiation of anticoagulation therapy in patients with atrial fibrillation by Health Areas (HA) in the region of Valencia in Spain and to quantify the influence of the HAs on variations in treatment choice. Methods: We conducted a population-based retrospective cohort study of all atrial fibrillation patients who started treatment with oral anticoagulants between November 2011 and February 2014 in each of the region's 24 HAs. We described patient and utilization characteristics per HA and initiation patterns over time, and we identified contextual and individual factors associated with differences in initiation patterns. Results: 21,879 patients initiated treatment with an oral anticoagulant in the 24 HAs. Initiation with direct oral anticoagulants (DOAC) in the first year was 14.6%. In November 2013 the ratio was 25.4%, with HA ratios ranging from 3.8 to 57.1%. DOAC-initiating patients had less comorbidity but were more likely to present episodes of previous ischemic stroke, hemorrhagic stroke, or TIA when compared with patients initiating with VKA treatment. Variability among HAs was statistically significant, with the majority of HAs ranking above or below the regional initiation average (ICC ≈ 8%). Conclusion: There was high variability in the percentage of DOAC initiation and in the choice of DOAC among HAs. Interventions aimed to improve DOAC initiation decision-making and to reduce variations should take into account the Health Area component. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 8 | 57% |
| Switzerland | 1 | 7% |
| Unknown | 5 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 79% |
| Scientists | 2 | 14% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 19% |
| Student > Master | 4 | 15% |
| Researcher | 4 | 15% |
| Librarian | 1 | 4% |
| Professor | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 9 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 11% |
| Nursing and Health Professions | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 8 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2017.
All research outputs
#3,634,040
of 22,999,744 outputs
Outputs from Frontiers in Pharmacology
#1,576
of 16,305 outputs
Outputs of similar age
#64,888
of 317,235 outputs
Outputs of similar age from Frontiers in Pharmacology
#23
of 250 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,305 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,235 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 250 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.